Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry by Dimitrios A. Pappas et al.
ORIGINAL RESEARCH
Dosing of Intravenous Tocilizumab in a Real-World
Setting of Rheumatoid Arthritis: Analyses
from the Corrona Registry
Dimitrios A. Pappas . Ani John . Jeffrey R. Curtis . George W. Reed .
Chitra Karki . Robert Magner . Joel M. Kremer . Ashwini Shewade .
Jeffrey D. Greenberg
Received: December 2, 2015 / Published online: February 8, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: In the United States, the
recommended starting dose of intravenous
tocilizumab (TCZ) is 4 mg/kg every 4 weeks,
with an increase to 8 mg/kg based on clinical
response for patients with moderate to severe
rheumatoid arthritis; however, data on how
TCZ dose is escalated in real life are missing. The
objective of this analysis was to describe
patterns of early intravenous TCZ dose
escalation in a real-world setting using data
from the Corrona registry.
Methods: All patients enrolled in the
comparative effectiveness substudy (CERTAIN)
nested within Corrona who initiated TCZ and
completed 3- and 6-month study visits were
eligible for inclusion. Patients who initiated
TCZ 4 mg/kg were categorized into 1 of 2
groups: those who remained on TCZ 4 mg/kg
at 3 months (Group 1) and those who escalated
to TCZ 8 mg/kg by or at 3 months (Group 2).
Changes in clinical disease activity measures
were provided.
Results: Of the 213 patients who were eligible
for analysis, 86 (40.4%) remained on their initial
dose of TCZ 4 mg/kg (Group 1) and 110 (51.6%)
were escalated to TCZ 8 mg/kg by or at 3 months
(Group 2). Baseline demographic and clinical
characteristics were similar between the 2
groups; except in Group 2, patients were older
(58.3 vs. 54.0 years) and a lower proportion was
female (75.5% vs. 89.4%) than in Group 1.
Significant improvements in disease activity
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measures were observed at 3 and 6 months in
both groups, with the majority of patients in
both groups achieving moderate or good
European League Against Rheumatism response.
Conclusion: Real-world data demonstrated that
physicians escalate TCZ dose at varying
frequencies. The ability to administer TCZ in
varying doses allows physicians to tailor TCZ
therapy to disease activity.
Trial registration: ClinicalTrials.gov identifier,
NCT01625650.
Keywords: Biologic agents; Disease-modifying
antirheumatic drugs; Prescribing patterns;
Registry; Rheumatoid arthritis; Tocilizumab
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic
autoimmune inflammatory disorder of the
joints that, if left untreated, leads to joint
damage and disability. Conventional synthetic
disease-modifying antirheumatic drugs
(csDMARDs) are recommended as first-line
therapy for patients with RA, with the goal of
achieving remission or low disease activity [1,
2]. However, a proportion of patients fail to
achieve this goal with csDMARDs alone, and
the addition of or switch to a biologic DMARD,
such as tocilizumab (TCZ), may provide
increased efficacy [1, 2].
Tocilizumab is the first approved drug for RA
that inhibits the interleukin 6 (IL-6) receptor
alpha. TCZ is approved for the treatment of
patients with moderate to severe active RA who
have had an inadequate response to one or
more DMARDs [3]. TCZ has been approved to be
used in combination with csDMARDs or as
monotherapy, making it an attractive therapy
for patients who cannot tolerate csDMARDs
[4–7]. In addition, intravenous TCZ can be
administered in 2 different doses (4 and 8 mg/
kg) and adjusted to the individual patient’s
disease activity.
The recommended dosing regimen of
intravenous TCZ varies around the world. In
European countries and Japan, the
recommended starting dose of TCZ is 8 mg/kg
every 4 weeks. In the United States (US), the
recommended starting dose of intravenous TCZ
for patients with moderate to severe RA, either
as in combination with csDMARDs or as a
monotherapy, is 4 mg/kg every 4 weeks. The
dose may be increased to 8 mg/kg based on
clinical response, at the physician’s discretion
[3]. Data from clinical trials have shown
significant efficacy with both the 4- and 8-mg/
kg doses of TCZ in patients with RA [8–13].
Overall, patients were more likely to achieve
better disease activity responses with TCZ 8 mg/
kg than with TCZ 4 mg/kg, but individual
responses varied [8–13]. In real-world settings
in the US, the option to change the dose of TCZ
based on clinical response allows physicians to
tailor the treatment dose to the disease activity;
however, data on dose escalation in everyday
practice are limited. This descriptive analysis
provides data on dosing patterns in the US,
where there is higher variability in TCZ dosing
than in other countries.
The objective of this analysis was to describe
the patterns of intravenous TCZ dose escalation
in a real-world clinical setting over 6 months of
therapy using data from a large, observational
US patient registry (Corrona). Descriptive data
showing changes in clinical disease activity,
functional status, and inflammatory markers at
3 and 6 months after therapy with different
dose escalation patterns of TCZ were also
provided.
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METHODS
Corrona Study Population
Patients enrolled in the Corrona registry and
participating in the CERTAIN (Comparative
Effectiveness Registry to Study Therapies for
Arthritis and Inflammatory Conditions)
substudy were included in this analysis. The
Corrona registry is an independent, prospective
observational cohort of patients with RA.
Details of the Corrona registry design have
been previously described [14].
CERTAIN Substudy
The CERTAIN study (ClinicalTrials.gov
identifier, NCT01625650) was nested within
Corrona and was designed to investigate
comparative effectiveness and comparative
safety of approved biologics for the treatment
of RA [15]. CERTAIN included 43 sites involving
[100 physicians. For enrollment into CERTAIN,
patients C18 years of age were required to have
moderate or high RA disease activity, defined as
Clinical Disease Activity Index (CDAI)[10, and
have had a first-time initiation of a biologic
agent for the treatment of RA. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. All patients in
CERTAIN provided written informed consent
for participation. The protocol was approved by
the institutional review boards of participating
academic sites and a central institutional review
board for private practice sites.
A total of 2358 patients were enrolled and
had C1 biologic initiation. The decision to start
a particular biologic and offer patient
enrollment in CERTAIN was at the discretion
of the treating physician; patients were not
randomized. Patients were enrolled in the study
at the time of biologic initiation and were
followed every 3 months until completion of
12 months of follow-up, unless they switched or
discontinued the biologic earlier. Patient
enrollment in the CERTAIN study was
completed on April 30, 2014. Upon
completion of participation in CERTAIN,
patients were rolled over to the main Corrona
RA registry for long-term safety follow-up.
Study Population
This analysis was restricted to those patients
enrolled in CERTAIN who initiated intravenous
TCZ between November 11, 2010 and August
29, 2013 and for whom 3- and 6-month
follow-up data were available by March 2014.
There were 138 patients who did not have a visit
beyond 3 months and were not included in this
analysis. Of these, 4 patients were excluded at
baseline, 54 patients did not have the
opportunity to have a 3- and 6-month
follow-up visit, and 80 patients exited
CERTAIN prior to their 6-month visit. Among
patients who exited CERTAIN early, 63 patients
discontinued TCZ prior to the 6-month visit
and 15 patients withdrew from the study
without stopping treatment.
Statistical Analysis
Patients were categorized in separate dosing
pattern groups based on TCZ dose information
collected at baseline, 3 and 6 months. Data were
analyzed from patients who started TCZ therapy
at 4 mg/kg and either remained on their initial
TCZdoseof4 mg/kgat3 months (Group 1)orhad
their initial TCZ dose of 4mg/kg escalated to TCZ
8 mg/kg by or at 3 months (Group 2). Patients
who had their dose escalated after 3 months were
Rheumatol Ther (2016) 3:103–115 105
included inGroup1 for this analysis. Patientswho
started TCZ at a dose of 8 mg/kg or who increased
and subsequently decreased the TCZ dose were
categorized ina separategroup (Group 3).Patients
who discontinued TCZ for any reason prior to the
6-month follow-up visit were not included in this
analysis.
Study questionnaires were designed to
capture whether any changes in TCZ dose
occurred between visits; however, exact dates
of dose changes were not captured unless the
change in TCZ dose occurred at the time of the
CERTAIN follow-up visit.
Clinical data were collected in CERTAIN for
patients at baseline and at 3, 6, 9, and
12 months; however, for this analysis, data
were restricted to those collected at 3 and
6 months due to the low number of patients
who had data beyond 6 months. These
assessments included Disease Activity Score in
28 joints using C-reactive protein (DAS28-CRP),
CDAI, CRP, modified Health Assessment
Questionnaire (mHAQ), patient pain, patient
fatigue, and European League Against
Rheumatism (EULAR) response. Clinical
disease activity levels at 3 and 6 months for
the 2 dosing pattern groups were calculated and
included the proportion of patients in each
group who achieved remission (CDAI B2.8) or
low disease activity (CDAI B10), the minimal
clinically important difference (MCID) for
CDAI, DAS28-CRP remission (DAS28-CRP
\2.32), DAS28-CRP low disease activity
(DAS28-CRP \2.67), and EULAR responses
(good, moderate, or no response) at 3 and
6 months. The MCID was defined as a decrease
in CDAI of C6 in patients with a baseline CDAI
between 10 and 22 (moderate disease activity)
and as a decrease in CDAI of C11 in patients
with a baseline CDAI[22 (high disease activity)
[16]. Other measures included the median
change from baseline in CDAI, DAS28-CRP,
CRP, patient pain, patient fatigue, and mHAQ
scores at 3 and 6 months.
RESULTS
TCZ Dosing Patterns
As of August 29, 2013, there were a total of 213
patients eligible for inclusion in this analysis;
199 patients (93.4%) initiated TCZ at 4 mg/kg
and 14 patients (6.6%) initiated TCZ at 8 mg/kg
(Fig. 1). Among the 199 patients who initiated
TCZ at 4 mg/kg, 86 (40.3% of the total
population) were escalated to TCZ 8 mg/kg
after the 3-month visit and by the 6-month
follow-up visit (Group 1), and 110 (51.6% of the
total population) were escalated to TCZ 8 mg/kg
by or at 3 months and remained on this dose
during the observation period (Group 2). The
remaining patients (Group 3) consisted of three
individuals whose TCZ dose was escalated from
4 to 8 mg/kg at 3 months before it was returned
to 4 mg/kg at 6 months, and an additional 14
who initiated TCZ at 8 mg/kg and were thus
unable to have their treatment escalated
(Fig. 1). These patients were excluded from
further analysis due to the small sample size.
Within Group 1, 45 patients remained on
their initial TCZ dose of 4 mg/kg through
6 months and 41 patients had their TCZ dose
escalated to 8 mg/kg by 6 months (i.e., any time
after the 3-month visit and prior to the 6-month
visit). Within Group 2, 82 patients had their
dose escalated prior to the 3-month visit and
28 patients had their dose escalated at the time
of the 3-month visit.
Baseline Characteristics
The majority of the 213 patients eligible for
analysis were female and white, with a median
age of 56.5 years (Table 1). At baseline, patients
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had established, advanced disease, with a
median disease duration of 11.2 years, a
median CDAI of 31.8, and a median mHAQ
score of 0.6. Most patients (95.8%) had previous
exposure to biologics (median, 2.0 prior
biologics). Baseline patient demographic and
clinical characteristics for the 2 dosing groups
(Group 1 and Group 2) were mostly similar
(Tables 2, 3). Patients in both groups had
similar mean (SD) duration of RA [10.9 (8.7)
years and 11.6 (8.9) years for Groups 1 and 2,
respectively] and high mean baseline disease
activity (Table 2), and the majority had a
history of multiple biologic DMARD treatment
failures prior to initiation of TCZ (Table 3).
Patients in Group 1 were younger in age
(mean, 54.0 vs. 58.3 years) and a higher
proportion were female (89.4% vs. 75.5%)
compared with patients in Group 2.
Approximately 30% of patients received TCZ
as monotherapy and 50% of patients received
concomitant methotrexate and the proportions
of patients receiving concomitant csDMARDs
were similar between the dosing groups
(Table 3).
Disease Activity, Functional Status,
and CRP at 3 and 6 Months in Patients
Who Did Not Escalate TCZ Dose
by 3 Months (Group 1)
Of the patients who continued to receive TCZ
4 mg/kg at 3 months (Group 1), at 3 and
6 months, respectively, 62% and 68% had
Fig. 1 Summary of
patient distribution
by TCZ dosing pat-
terns over the ﬁrst
6 months of therapy.
Orange circles repre-
sent the administra-
tion of a TCZ dose
of 4 mg/kg at the
speciﬁed visit and blue
circles represent a
TCZ dose of 8 mg/
kg. TCZ Tocilizumab
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achieved an MCID based on CDAI, 40% and
45% had achieved DAS28-CRP low disease
activity or remission, and 57% and 65% had
achieved a moderate or good EULAR response
(Fig. 2a). In addition, patients in Group 1
exhibited decreases in all disease activity
measures (CDAI, DAS28-CRP, pain, fatigue,
and CRP) at 3 and 6 months from baseline
(Fig. 2b). The median (interquartile range [IQR])
decrease from baseline in mHAQ at 3 and
6 months was 0.0 (-0.3 to 0.0) and 0.0 (-0.3
to 0.0), respectively, for patients in Group 1 (not
shown).
Disease Activity, Functional Status,
and CRP at 3 and 6 Months in Patients
Who Escalated TCZ Dose by or at 3 Months
(Group 2)
Of the patients who escalated to TCZ 8 mg/kg
by or at 3 months (Group 2), at 3 and 6 months,
respectively, 55% and 67% had achieved an
MCID based on CDAI, 50% and 67% had
achieved DAS28-CRP low disease activity or
remission, and 59% and 66% had achieved a
moderate or good EULAR response (Fig. 3a).
Similar to patients in Group 1, patients in
Group 2 exhibited decreases in all disease
activity measures (CDAI, DAS28-CRP, pain,
fatigue, and CRP) at 3 and 6 months from
baseline (Fig. 3b). The median (IQR) decrease
from baseline in mHAQ at 3 and 6 months was
0.0 (-0.3 to 0.0) and 0.0 (-0.4 to 0.0),
respectively, for patients in Group 2 (not
shown).
DISCUSSION
This study, among the first to describe how TCZ
dose is being escalated in real-world settings in
the US, found that most patients have their
dose escalated within 6 months of initiation.
Patients in the US generally initiate TCZ at
4 mg/kg, and physicians have the choice
whether and when to escalate the dose to
8 mg/kg. Data from this group of patients
from the CERTAIN study demonstrated that
US physicians escalate the dose of TCZ at
varying frequencies, with favorable results in
terms of response of disease activity and other
effectiveness measures, including
patient-reported outcomes. Of the 213 patients
Table 1 Baseline demographic and clinical characteristics
for all eligible patients
Characteristics All eligible patients
(N5 213)
Age, mean (SD), years 56.5 (12.9)
Female, % 82.1
White, % 86.4
Duration of RA, mean (SD), years 11.2 (8.7)
Weight, mean (SD), kg 84.3 (22.3)
RF or ACPA seropositive, % 58.7
CDAI, mean (SD) 31.8 (13.3)
DAS28-CRP, mean (SD) 5.0 (1.1)
CRP, mean (SD), mg/L 11.4 (17.4)
Patient pain, mean (SD) 58.2 (24.5)
Patient fatigue, mean (SD) 59.6 (27.6)
mHAQ, mean (SD) 0.6 (0.6)
HAQ-DI, mean (SD) 1.2 (0.7)
Biologic naive, % 4.2
No. of prior biologics,
median (IQR)
2.0 (1.0–3.0)
ACPA Anti-cyclic citrullinated peptide antibody, CDAI
Clinical Disease Activity Index, CRP C-reactive protein,
DAS28-CRP Disease Activity Score in 28 joints using
CRP, HAQ-DI Health Assessment Questionnaire
Disability Index, IQR Interquartile range, mHAQ
Modiﬁed Health Assessment Questionnaire, RA
Rheumatoid arthritis, RF Rheumatoid factor
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eligible for this analysis, 93.4% initiated TCZ at
4 mg/kg, and by 6 months, 77% of patients were
receiving TCZ 8 mg/kg. All of the 14 patients
who initiated TCZ at 8 mg/kg were receiving
TCZ 8 mg/kg at 6 months; 2 of these patients
had had their dose decreased by or at 3 months
followed by escalation back to TCZ 8 mg/kg by
6 months. Of the patients who initiated TCZ at
4 mg/kg, 57% had their TCZ dose escalated by
or at 3 months, rising to 76% by 6 months.
Baseline disease activity and prior medication
history were similar between patients who
escalated during the initial 3-month period
and patients who did not; however, patients
who escalated by or at 3 months were older and
more likely to be male. Improvements in all
disease activity measures were observed at 3 and
6 months after the initiation of TCZ in both
groups of patients.
The patients in this analysis had established
disease of long duration, high disease activity at
baseline, and failure of other biologic agents
prior to therapy with TCZ, indicating a
population rather refractory to therapy. In this
population, the majority of patients achieved a
moderate or good EULAR response regardless of
the dosing pattern, complementing the efficacy
data of TCZ stemming from clinical trials [6, 9,
Table 2 Baseline demographic and clinical characteristics by dose escalation group
Characteristics Group 1: No dose escalation
by or at 3 months (n5 86)
Group 2: Dose escalation by or
at 3 months (n5 110)
Age, mean (SD), yearsa 54.0 (11.8) 58.3 (13.4)
Female, %a 89.4 75.5
White, % 81.4 90.0
Duration of RA, mean (SD), years 10.9 (8.7) 11.6 (8.9)
Weight, mean (SD), kg 86.2 (22.4) 83.7 (22.8)
RF or ACPA seropositive, % 55.4 58.4
CDAI, mean (SD) 32.4 (13.9) 31.3 (12.9)
DAS28-CRP, mean (SD) 5.1 (1.1) 5.0 (1.2)
CRP, mean (SD), mg/L 10.4 (15.1) 13.0 (20.2)
Patient pain, mean (SD) 57.4 (23.8) 58.6 (24.4)
Patient fatigue, mean (SD) 59.2 (28.6) 58.9 (27.0)
mHAQ, mean (SD) 0.6 (0.6) 0.7 (0.5)
HAQ-DI, mean (SD) 1.2 (0.7) 1.2 (0.7)
Biologic naive, % 2.3 4.6
No. of prior biologics, median (IQR) 2.0 (1.0–4.0) 2.0 (1.0–3.0)
ACPA Anti–cyclic citrullinated peptide antibody, CDAI Clinical Disease Activity Index, CRP C-reactive protein,
DAS28-CRP Disease Activity Score in 28 joints using CRP, HAQ-DI Health Assessment Questionnaire Disability Index,
IQR interquartile range, mHAQ Modiﬁed Health Assessment Questionnaire, RA Rheumatoid arthritis, RF Rheumatoid
factor
a P\0.05. P values based on the t test to compare means and the Fisher exact test to compare binary outcomes between
dose escalation groups
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10, 17]. The favorable responses observed in
both dosing groups, regardless of whether TCZ
was initiated as monotherapy or in
combination with csDMARDs, indicate that
participating physicians were responding
appropriately to disease activity levels, as
medication dosing was at their discretion
based on the CERTAIN protocol.
Although data directly comparing the 2
doses (4 vs. 8 mg/kg) are limited, clinical trials
comparing TCZ 4 mg/kg vs. placebo and TCZ
8 mg/kg vs. placebo have shown that a higher
proportion of patients receiving TCZ 8 mg/kg
achieved ACR responses at 6 months than
patients receiving TCZ 4 mg/kg [9, 10]. In one
trial, a greater reduction in DAS28 was observed
with TCZ 8 mg/kg than with TCZ 4 mg/kg as
early as 4 weeks after initiating therapy [13]. In
the present analysis, a large proportion of
patients (76%) was found to have their dose
escalated by their physician within 6 months of
initiating treatment, indicating physicians
perceived the potential for a large proportion
of patients to experience improved clinical
response by escalating to TCZ 8 mg/kg vs.
remaining at TCZ 4 mg/kg; however, both
groups of patients (those who escalated by or
at 3 months and those who did not) exhibited
significant improvements in disease activity
levels at both 3 and 6 months. These data
suggest that in real-world settings, physicians
respond to disease activity levels and that the
option to adjust TCZ dose based on individual
clinical responses may have provided an
additional benefit to the patients.
In this study, only 22.6% of patients
remained at the TCZ 4-mg/kg dose 6 months
after initiation of therapy and 1.5% returned to
4 mg/kg after an initial increase to 8 mg/kg.
While it is likely that dose reductions in these
patients were due to safety concerns, previous
studies have shown that a sufficient response
with TCZ 8 mg/kg may warrant dose reduction.
In a retrospective study of 22 patients with RA
who received TCZ 8 mg/kg for 6 months and
had their dose tapered to 4 mg/kg because of
low disease activity, 55% of patients remained
in disease remission 6 months after the dose
Table 3 Concomitant medications at baseline by dose escalation group in patients initiating TCZ at 4 mg/kg
Baseline medications Group 1: No dose escalation
by or at 3 months (n5 86)
Group 2: Dose escalation by or
at 3 months (n 5 110)
Currently receiving prednisone, % 30.2 24.6
\5 mg/day, % (n) 26.9 (7) 11.1 (3)
C5 mg/day, % (n) 73.1 (19) 88.9 (24)
Prednisone dose, median (IQR), mg/day 5.0 (4.0–10.0) 10.0 (5.0–10.0)
TCZ as monotherapy, % 33.7 28.2
Receiving concurrent DMARD, % 66.3 71.8
Methotrexate, % 50.0 50.0
Leﬂunomide, % 9.3 10.0
Sulfasalazine, % 2.3 4.6
Hydroxychloroquine, % 10.5 9.1
DMARD Disease-modifying antirheumatic drug, IQR interquartile range, TCZ tocilizumab
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Fig. 2 Disease activity (a) and functional status and CRP
(b) of patients in Group 1 (n = 86) at 3 and 6 months.
Patients in Group 1 remained on TCZ 4 mg/kg at
3 months and either did not have their dose escalated by
6 months (n = 45) or had it escalated between 3 and
6 months (n = 41). Median (IQR) decrease from baseline
in mHAQ at 3 months was 0.0 (-0.3 to 0.0) and 0.0
(-0.3 to 0.0) for patients in Group 1 and Group 2,
respectively. MCID was deﬁned as a decrease in CDAI of
C6 in patients with a baseline CDAI between 10 and 22
(moderate disease activity) and as a decrease in CDAI of
C11 in patients with a baseline CDAI[22 (high disease
activity). CDAI Clinical Disease Activity Index, CRP
C-reactive protein, DAS28-CRP Disease Activity Score in
28 joints using CRP, EULAR European League Against
Rheumatism, IQR Interquartile range, LDA Low disease
activity, MCID Minimal clinically important difference,
mHAQ Modiﬁed Health Assessment Questionnaire
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Fig. 3 Disease activity (a) and functional status and CRP
(b) of patients in Group 2 (n = 110) at 3 and 6 months.
Patients in Group 2 had their dose escalated from TCZ
4 mg/kg to TCZ 8 mg/kg prior to 3 months (n = 82) or at
3 months (n = 28). Median (IQR) decrease from baseline
in mHAQ at 6 months was 0.0 (-0.3 to 0.0) and 0.0 (-0.4
to 0.0) for patients in Group 1 and Group 2, respectively.
MCID was deﬁned as a decrease in CDAI of C6 in patients
with a baseline CDAI between 10 and 22 (moderate disease
activity) and as a decrease in CDAI of C11 in patients with
a baseline CDAI[22 (high disease activity). CDAI Clinical
Disease Activity Index, CRP, C-reactive protein,
DAS28-CRP Disease Activity Score in 28 joints using
CRP, EULAR European League Against Rheumatism, IQR
Interquartile range, LDA Low disease activity, MCID
Minimal clinically important difference, mHAQ Modiﬁed
Health Assessment Questionnaire
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reduction [18]. Importantly, patients with
worsened disease activity after dose reduction
regained low disease activity after having their
dose escalated back to 8 mg/kg.
A limitation of this study was that the
CERTAIN study design did not capture the
exact timing of dose changes if they occurred
between visits; only the medication dose and
frequency were captured at the time of each
CERTAIN follow-up visit. In these cases,
CERTAIN summarized only the change in dose
that happened between visits, not on the exact
date. Thus, a change prior to the 3-month visit
could have occurred very close to the baseline
visit or very close to the 3-month visit. In the
unlikely event that[1 change in dose occurred
between visits, CERTAIN captured only themost
recent change. As a result, a more detailed
description of dose changes was not possible. In
addition, observational data from registries are
always subject to skepticism about
generalizability of findings; however, CERTAIN
was deployed in almost half of the Corrona
participating practices withwide geographic and
practice type distribution. Furthermore, the
inclusion criteria of the study may add a further
limit to the generalizability of our findings. In
addition, it is important to note that this study
did not aim to compare the effectiveness of the
different escalation patterns and no adjusted
effectiveness analyses took place; therefore, the
overall favorable effect of the 2 dosing schemas
can be attributed only to physicians responding
to patients’ disease activity appropriately and
adjusting TCZ dose accordingly.
CONCLUSIONS
In conclusion, real-world data from the Corrona
registry demonstrated that in this population of
patients with significant disease burden and
prior exposure to biologics, physicians escalated
the dose of TCZ at varying frequencies, with the
majority of patients having their dose escalated
by or at 3 months. In this descriptive analysis
the majority of patients in both TCZ dosing
patterns achieved moderate or good EULAR
response and experienced improvement in
effectiveness outcomes, indicating that
physicians adjusted TCZ dose appropriately,
taking advantage of the option to tailor TCZ
dose based on clinical response.
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